Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer
Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies i...
Gespeichert in:
| Veröffentlicht in: | Oncology 2011-01, Vol.80 (1-2), p.130-134 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 134 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 130 |
| container_title | Oncology |
| container_volume | 80 |
| creator | Atmaca, Akin Pauligk, Claudia Steinmetz, Kristina Altmannsberger, Hans-Michael Jäger, Elke Al-Batran, Salah-Eddin |
| description | Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial. Results: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. Conclusion: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy. |
| doi_str_mv | 10.1159/000329063 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_miscellaneous_878823734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>878823734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-a3cbe69aeacd39ca21e45e4d8525b719800e48f00a9488c6e5d24cc299ff99593</originalsourceid><addsrcrecordid>eNpd0UtvEzEQAGALgWgoHLgjZCEhxGHBr_XaxyoqbdVW5ADn1cQ7m7hs1lvbAcqvx21CKnEaa_R5ZjRDyGvOPnFe28-MMSks0_IJmXElZMWEFE_JrKRZJRRXR-RFSjeFNbXSz8mR4LppVG1m5M8ihtUYUvaOXmwmcJmGni7WIU3rEO8GyNjRa5_DCsfqxGX_8yFTfmX0I730IySkp7-niCn5MNKSXED2OOZEf_m8pteYIWW4b3BWHrHEOYwO40vyrIch4at9PCbfv5x-m59XV1_PLuYnV5WTWuQKpFuitoDgOmkdCI6qRtWZWtTLhlvDGCrTMwZWGeM01p1Qzglr-97a2spj8mFXd4rhdosptxufHA4DjBi2qTWNMUI2UhX57j95E7ZxLMO1hXCtmeYFfdwhF0NKEft2in4D8a7lrL0_R3s4R7Fv9wW3yw12B_lv_wW83wNIDoY-ls349OiUZJIrVtybnfsBcYXxAPZ9_gL9_puc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>882166061</pqid></control><display><type>article</type><title>Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Karger E-Journals</source><creator>Atmaca, Akin ; Pauligk, Claudia ; Steinmetz, Kristina ; Altmannsberger, Hans-Michael ; Jäger, Elke ; Al-Batran, Salah-Eddin</creator><creatorcontrib>Atmaca, Akin ; Pauligk, Claudia ; Steinmetz, Kristina ; Altmannsberger, Hans-Michael ; Jäger, Elke ; Al-Batran, Salah-Eddin</creatorcontrib><description>Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial. Results: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. Conclusion: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000329063</identifier><identifier>PMID: 21677458</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomarkers ; Cancer ; Cell Line, Tumor ; Cell Proliferation ; Clinical Translational Research ; Disease-Free Survival ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunochemistry ; Kaplan-Meier Estimate ; Medical prognosis ; Medical sciences ; Metastasis ; Mitogen-Activated Protein Kinase 1 - metabolism ; Mitogen-Activated Protein Kinase 3 - metabolism ; Phosphorylation ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Stomach ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - mortality ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Survival Rate ; Treatment Outcome ; Tumors ; Ubiquitin-Protein Ligases - metabolism</subject><ispartof>Oncology, 2011-01, Vol.80 (1-2), p.130-134</ispartof><rights>2011 S. Karger AG, Basel</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 S. Karger AG, Basel.</rights><rights>Copyright (c) 2011 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-a3cbe69aeacd39ca21e45e4d8525b719800e48f00a9488c6e5d24cc299ff99593</citedby><cites>FETCH-LOGICAL-c362t-a3cbe69aeacd39ca21e45e4d8525b719800e48f00a9488c6e5d24cc299ff99593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24303140$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21677458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atmaca, Akin</creatorcontrib><creatorcontrib>Pauligk, Claudia</creatorcontrib><creatorcontrib>Steinmetz, Kristina</creatorcontrib><creatorcontrib>Altmannsberger, Hans-Michael</creatorcontrib><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>Al-Batran, Salah-Eddin</creatorcontrib><title>Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer</title><title>Oncology</title><addtitle>Oncology</addtitle><description>Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial. Results: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. Conclusion: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Clinical Translational Research</subject><subject>Disease-Free Survival</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Mitogen-Activated Protein Kinase 1 - metabolism</subject><subject>Mitogen-Activated Protein Kinase 3 - metabolism</subject><subject>Phosphorylation</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Stomach</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Ubiquitin-Protein Ligases - metabolism</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0UtvEzEQAGALgWgoHLgjZCEhxGHBr_XaxyoqbdVW5ADn1cQ7m7hs1lvbAcqvx21CKnEaa_R5ZjRDyGvOPnFe28-MMSks0_IJmXElZMWEFE_JrKRZJRRXR-RFSjeFNbXSz8mR4LppVG1m5M8ihtUYUvaOXmwmcJmGni7WIU3rEO8GyNjRa5_DCsfqxGX_8yFTfmX0I730IySkp7-niCn5MNKSXED2OOZEf_m8pteYIWW4b3BWHrHEOYwO40vyrIch4at9PCbfv5x-m59XV1_PLuYnV5WTWuQKpFuitoDgOmkdCI6qRtWZWtTLhlvDGCrTMwZWGeM01p1Qzglr-97a2spj8mFXd4rhdosptxufHA4DjBi2qTWNMUI2UhX57j95E7ZxLMO1hXCtmeYFfdwhF0NKEft2in4D8a7lrL0_R3s4R7Fv9wW3yw12B_lv_wW83wNIDoY-ls349OiUZJIrVtybnfsBcYXxAPZ9_gL9_puc</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Atmaca, Akin</creator><creator>Pauligk, Claudia</creator><creator>Steinmetz, Kristina</creator><creator>Altmannsberger, Hans-Michael</creator><creator>Jäger, Elke</creator><creator>Al-Batran, Salah-Eddin</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer</title><author>Atmaca, Akin ; Pauligk, Claudia ; Steinmetz, Kristina ; Altmannsberger, Hans-Michael ; Jäger, Elke ; Al-Batran, Salah-Eddin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-a3cbe69aeacd39ca21e45e4d8525b719800e48f00a9488c6e5d24cc299ff99593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Clinical Translational Research</topic><topic>Disease-Free Survival</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Mitogen-Activated Protein Kinase 1 - metabolism</topic><topic>Mitogen-Activated Protein Kinase 3 - metabolism</topic><topic>Phosphorylation</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Stomach</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Ubiquitin-Protein Ligases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atmaca, Akin</creatorcontrib><creatorcontrib>Pauligk, Claudia</creatorcontrib><creatorcontrib>Steinmetz, Kristina</creatorcontrib><creatorcontrib>Altmannsberger, Hans-Michael</creatorcontrib><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>Al-Batran, Salah-Eddin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atmaca, Akin</au><au>Pauligk, Claudia</au><au>Steinmetz, Kristina</au><au>Altmannsberger, Hans-Michael</au><au>Jäger, Elke</au><au>Al-Batran, Salah-Eddin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>80</volume><issue>1-2</issue><spage>130</spage><epage>134</epage><pages>130-134</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial. Results: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. Conclusion: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>21677458</pmid><doi>10.1159/000329063</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 2011-01, Vol.80 (1-2), p.130-134 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_878823734 |
| source | MEDLINE; Alma/SFX Local Collection; Karger E-Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers Cancer Cell Line, Tumor Cell Proliferation Clinical Translational Research Disease-Free Survival Gastroenterology. Liver. Pancreas. Abdomen Humans Immunochemistry Kaplan-Meier Estimate Medical prognosis Medical sciences Metastasis Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - metabolism Phosphorylation Predictive Value of Tests Prognosis Proportional Hazards Models Retrospective Studies Stomach Stomach Neoplasms - drug therapy Stomach Neoplasms - metabolism Stomach Neoplasms - mortality Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Rate Treatment Outcome Tumors Ubiquitin-Protein Ligases - metabolism |
| title | Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A28%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Impact%20of%20Phosphorylated%20Mitogen-Activated%20Protein%20Kinase%20Expression%20in%20Patients%20with%20Metastatic%20Gastric%20Cancer&rft.jtitle=Oncology&rft.au=Atmaca,%20Akin&rft.date=2011-01-01&rft.volume=80&rft.issue=1-2&rft.spage=130&rft.epage=134&rft.pages=130-134&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000329063&rft_dat=%3Cproquest_karge%3E878823734%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=882166061&rft_id=info:pmid/21677458&rfr_iscdi=true |